Page 20 - Sun Pharma

More pressure ahead for Sun Pharma stock

Significant price erosion in the US market and lack of triggers, product pipeline are key worries

Sun Pharma expects FY18 revenues to decline due to pricing pressure in US

Firm plans to spend up to 10% of its revenues on R&D activities

Sun Pharma stares at sharp earnings downgrades

A muted revenue outlook and higher costs will keep margins and earnings under pressure in FY18

Sun Pharma slips to Rs 424 cr Q1 loss on weak sales, anti-trust settlement

An one-off Rs 950 crore payment to settle an anti trust litigation coupled with weak performance in core India and US markets resulted in Sun Pharmaceutical Industries posting Rs 424 crore loss in first quarter FY 2018. In same period last year the company had posted a profit of Rs 2037 crore. Revenue dipped 23 per cent to Rs 6167 crore owing to continued pricing pressure in the US, regulatory challenges and GST-led de stocking in the domestic market. Domestic sales declined 5 per cent while US market revenue was down 42 per cent. The company's US subsidiary has seen 30 per cent decline in sales on a year on year basis. Also the first quarter sales in last fiscal had a high base impact owing to the as the six months exclusivity in sale of anti-leukemia drug Gleevec. Overall pricing pressure also impacted the growth. Profit before tax and exceptional items fell 70 per cent to Rs 791 crore. A Rs 950 crore outgo to settle a litigation in the US dragged the company to loss.Sun Pharma ...

Sun Pharma, 10 others settle insider trading case with Sebi

Sebi's High Powered Advisory Committee recommended the case for settlement on the payment of Rs 18 L

Sun Pharma posts net loss of Rs 425 cr in Q1 on one-off charge

US sales drop 42%; Rs 950-cr charge related to settlement of antitrust case in US

39 stocks from BSE 500 index hit 52-week lows

Tata Motors, Sun Pharma, Dr Reddy's Lab, Coal India and Amara Raja Batteries hit 52-week lows

Sun Pharma's stock dips before Q1 results

Sun Pharmaceutical Industries hit a four-year low of Rs 451 a share on the BSE exchange, a day before the largest medicine exporter is to announce its quarterly results. The stock had fallen five per cent on Wednesday to Rs 474.7, after a 31 per cent drop in sales for US subsidiary Taro. The company had cited a "difficult generic pricing environment" for the downfall.This has mean a nearly 20 per cent drop in the share over 16 trading sessions since the recent high of Rs 588 on July 19. A Bloomberg poll average of 18 analysts says the company is expected to report a 42 per cent decline in net profit for the quarter ending June, due to shrinking margin from the US business. Sun Pharma is also facing a challenge in its earnings. Its unit at Halol in Gujarat continues to be under the US sector regulator, the FDA's watch, hitting sales and profit in the biggest international market. The facility, catering to the US market, first got a warning letter from the FDA in 2015. Even after ...

Sun Pharma hits 52-week low on Taro's weak June quarter results

The stock slipped 5% to Rs 475, also its 52-week low on BSE in early morning trade.

Sun Pharma inks $55.5mn deal with Samsung BioLogics for anti-psoriasis drug

The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea

Sun Pharma to develop chikungunya, zika drugs

Sun Pharmaceutical Industries has tied up with Pune-based National Institute of Virology to develop new drugs to treat chickungunya, dengue and zika. The partnership is a part of company's plans to develop drugs which cater to unmet needs of patients. Currently there are no vaccines or specific drugs to treat them and thus pose a health concern globally.Under the agreement NIV will conduct the tests on biological, chemical and phytopharmaceutical (plant based) molecules developed by the company against the viruses." We will work with NIV on pre-clinical studies and based on the results we will conduct clinical trials," said Dr Altaf Lal, senior adviser (global health and innovation), Sun Pharma.Sun Pharma did not disclose project funding and commercial development details.The tie up is also in sync with government's Make in India plan, the company said. Sun Pharma's agreement with NIV follows its MoU with Indian Council for Medical Research for conducting joint scientific research ...

Sun Pharma's extra discount to tide over GST wave

Sop for stockists to ensure easy availability of medicines

Sun Pharma's niche drug ramp-up key to growth

Despite the Zetia launch, FY18 could be subdued given pricing pressures

Sun Pharma wants to rise on niche route

Lost 50% market value in 2 years due to competition

Dilip Shanghvi repositions Sun Pharma in US as a specialty drugmaker

Company has lost 50% market value in 2 years due to competition

Pharma shares gain; Nifty Pharma index up 5% in three days

In past two weeks, till Monday, the pharma index tanked 15%, against 2% rise in Nifty 50 index.

Sun Pharma recalls 13,000 bottles of chewable Cetirizine for children in US

Sun Pharmaceutical Industries Inc is recalling 13,200 bottles of the tablets in the strength of 5 mg

Sun Pharma tanks 12% to hit its 52-week low; stock top Sensex loser

On the BSE, over 19 lakh shares exchanged hands against its two-week average of 5 lakh shares

Significant price erosion in US takes toll on Sun Pharma

After the disappointment by Taro (Sun Pharma's US subsidiary) earlier this week, the stage was set for a weak show by Sun Pharma in the March 2017 quarter (Q4). With premium pricing of products, Taro had so far driven US sales and margins of Sun Pharma, which faces delayed product approvals and launches on the back of the Warning letter issues by the US FDA to its Halol plant. With Taro's portfolio, primarily dermatology, under pricing pressure, Sun was bound to see pressure in US sales. However, Sun's results were way below expectations and hence, after Monday's cut due to Taro (Kotak Institutional Equities had cut FY18/19 estimates by three per cent each) analysts could further cut their earnings estimate.Taro contributes more than half to Sun's US sales, and saw revenues decline 26 per cent year-on-year in Q4; fall in operating and net profit was steeper at 44 per cent and 28 per cent. Sun's US sales at $381 million, thus fell by 34 per cent. Excluding Taro, the pressure on US ...

Sun Pharma Q4 net declines 14% to Rs 1,223 cr, warns of fall in FY18 sales

rmaceutical Industries has guided for a single digit decline in sales owing to regulatory challenges following a 14 per cent decline consolidated net profit in fourth quarter FY 18.Net profit for quarter dropped to Rs 1223 crore as against Rs 1416 crore in same period last year. Total revenue including other income fell 6.3 per cent to Rs 7361 crore on a year on year basis.Increased competition, pricing pressure and regulatory challenges continue to impact sales in US market and sales from the geography declined 34 per cent on a year on year basis. Sun Pharma's subsidiary Taro also reported a weak result and its sales were lower by 26 per cent. Also Sun Pharma's fourth quarter sales in last fiscal were boosted by contribution from its top selling anti leukemia drug Gleevec for which it had six months sales exclusivity.Sun Pharma's managing director Dilip Shanghvi said FY 18 will be a challenging year for the company and the company may see a single digit decline in revenue over FY ..